The Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics: Part B
Specificaties
Gebonden, blz.
|
Engels
Elsevier Science |
2022
ISBN13: 9780323910361
Rubricering
Onderdeel van serie
International Review of Movement Disorders
Levertijd ongeveer 9 werkdagen
Gratis verzonden
Samenvatting
The Neurobiology of the Gilles de la Tourette Syndrome and Chronic Tics, Part B, Volume Four reviews historical background, current nosology and guidelines. In addition, it includes an overview of pathophysiology, ranging from its genetic basis and changes in neurochemistry and electrophysiology to widespread neural circuits. Specific chapters cover The genetic basis of Gilles de la Tourette Syndrome, Genome-wide association study of Tourette Syndrome, De Novo mutations in Tourette Syndrome, Animal models for Tourette Syndrome, The neural-immune crosstalk in Tourette syndrome: from immunobiology to epistemology, Functional connectivity in the Gilles de la Tourette Syndrome, and much more.
Specificaties
Inhoudsopgave
<p>Preface<br>Marc E. Lavoie and Andrea E. Cavanna<br>1. The genetic basis of Gilles de la Tourette syndrome<br>Sarah B. Abdallah, Evan Realbuto, Mary Oluwatosin Kaka, Kelly Yang, Apostolia Topaloudi, Peristera Paschou, Jeremiah M. Scharf and Thomas V. Fernandez<br>2. Studying the pathophysiology of tic disorders in animal models<br>Christopher Pittenger<br>3. The neural-immune crosstalk in Tourette syndrome: From immunobiology to epistemology<br>Yasamin Mahjoub, Davide Martino and Andrea E. Cavanna<br>4. Functional connectivity in the Gilles de la Tourette syndrome<br>Matthew Feigelis and Deanna J. Greene<br>5. Perception-action integration in Gilles de la Tourette syndrome<br>Theresa Paulus, Christian Beste and Alexander Münchau<br>6. The pharmacological treatment of Tourette syndrome<br>José Fidel Baizabal-Carvallo and Joseph Jankovic<br>7. Ecopipam: A D1 receptor antagonist for the treatment of Tourette syndrome<br>Richard E. Chipkin, Donald L. Gilbert and Atul Mahableshwarkar<br>8. Atypical antipsychotics for treatment of Tourette syndrome<br>Vamsi K. Kalari, Peter E. Morrison and Cathy L. Budman<br>9. Alpha agonists for the treatment of Tourette syndrome<br>Nick Cothros and Tamara Pringsheim<br>10. Cannabinoids: Possible role in the pathophysiology and therapy of Gilles de la Tourette syndrome<br>Natalia Szejko and Kirsten Müller-Vahl<br>11. Novel potential avenues for the therapy of Tourette syndrome: Cannabinoid and steroid-based tools<br>Marco Bortolato and Roberto Cadeddu<br>12. Non-invasive brain stimulation for the treatment of Tourette's syndrome<br>Sneha Chenji, Kayla D. Stone and Frank P. MacMaster<br>13. Entrainment of movement-related brain oscillations to improve symptoms in Tourette syndrome<br>Mairi Houlgreave, Bàrbara Morera Maiquez, Katherine Dyke, Georgina Jackson and Stephen Jackson<br>14. Network oscillatory activity in chronic tics and Tourette syndrome<br>Joohi Jimenez-Shahed</p>